ADMEcell Will Be Exhibiting At The AAPS Meeting Oct 24-27 Booth #1559

Posted by Sandy Koshkin on Thu, Oct 13, 2011 @ 11:50 AM

ADMEcell To Exhibit At The AAPS Meeting IN Washington DC Oct 25-27

ADMEcell will join over 500 exhibitors at the upcoming AAPS meeting in Washinton DC October 25 through October 27.  This is the 25th anniversary of the AAPS meeting which will include speakers such as Janet Woodcock, M.D., director of the Center for Drug EvaluatioAAPS Meetingn and Research at the Food and Drug Administration, who will provide her view on the future of regulations. John Lechleiter, Ph.D., president and chief executive officer, Eli Lilly and Company, will speak to the future shape of the global pharmaceutical industry; Francis S. Collins, M.D., Ph.D., director, U.S. National Institutes of Health, will speak on current research that may lead to new therapies in the future. Sir Michael Rawlins, M.D., chairman of the National Institute of Health & Clinical Excellence (NICE) of the United Kingdom, will speak on the cost benefits of therapies and the societal ability to pay for the therapies, "Value for Money in Healthcare: The Future." NICE is an independent organization responsible for providing national guidance on promoting good health and preventing and treating ill health.

ADMEcell will showcase its three product lines for providing tools for drug discovery and development:

Cell based Assays: Caco-2, MDR-1, BCRP & BBB Permeability

ELISA Kits For Monoclonal Antibody Assessment: Quantification kits for Human, Mouse, Rat & Bovine IgG and Mouse Ig Isotyping

Protein Binding Kits For HAS and AGP

Please plan to visit us at Exhibit #1559

Tags: transporters, ELISA Kits, Human IgG Kits, Mouse IgG Kits, Rat Igg Kits, Mouse Isotyping Kits, Ready To Use Assays, Ready To Use Kits, aaps meeting, aaps exhibition, caco-2 assay, cell based assays, MDR1 Kits, Protein Binding Kits, Blood Brain Absorption Kits, Caco-2 Kits

Ready To Use Human/Mouse IgG Kits As Tools in Drug Discovery

Posted by Sandy Koshkin on Wed, Aug 24, 2011 @ 11:23 AM

Monoclonal AntibodiesThe economic recession has not inhibited the growth of FDA approved antibody drugs and the market for these drugs.  So far treatments for Cancer, Arthritis, Autoimmune diseases and Transplant rejection have dominated the class of drugs derived from monoclonal antibodies. The future products will include additional drugs for treatment of the above diseases and others such as Osteoporosis and Asthma.

Monoclonal antibody derived therapeutics have become a significant part of the overall drug market boasting over $40 billion in sales as of 2010 and is likely to double in the next ten years. The development of monoclonal  antibodies continues to grow and  clearly, faster ready-to-use kits to help rapid determination of the IgG levels in such antibodies remain important tools in the drug discovery and development process.

All major pharmaceutical and biotech companies have active programs in developing monoclonal antibodies. Smaller biotech companies focus on developing such antibodies only, whereas universities and research institutions utilize grants to discover new targets with monoclonal antibody technologies.

ADMEcell  and RD-Biotech (Besancon, France) offer a new line of Ready-To-Use 30 minute assay kits to quantitate Human, Mouse, Rat and Bovine IgG in cell culture supernatant, ascites and serum-all assays covering a wide dynamic range (i.e. 16-1000ng/ml for human IgG). Color coded buffer solutions simplify the pipetting steps.  Recombinant or fully humanized monoclonal antibodies can be assayed. Also included in the product line is the Mouse IGg sotyping kit.

Tags: Human IgG Kits, Mouse IgG Kits, Rat Igg Kits, Mouse Isotyping Kits, Monoclonal Antibodies